Abstract
Background Studies have shown that those with certain high-risk comorbidities such as diabetes, chronic kidney disease (CKD), chronic lung disease, or those with immunocompromising conditions have increased risk of hospitalization from COVID-19. Here we estimate the elevated risks of breakthrough infection and hospitalization in fully vaccinated individuals with comorbidities.
Methods Using a population of fully-vaccinated patients in the de-identified Truveta Platform of electronic health records from January 1, 2019, to January 10, 2022, we used logistic regression to estimate risk of 1) a patient experiencing a breakthrough COVID-19 infection after being fully vaccinated, and 2) rate of hospitalization in those experiencing breakthrough infection. Potential confounding was adjusted with inverse probability weighting for each comorbidity by age, race, ethnicity, and sex. We present ORs and percentages of breakthrough infections by comorbidity status.
Results Of 3,424,965 fully vaccinated patients, 2.79%, 2.63%, 2.38%, 1.83% with CKD, chronic lung disease, diabetes, and those in an immunocompromised state experienced breakthrough infection, respectively, compared to 1.95% in the overall population. All cormorbidities were associated with significantly increased odds of breakthrough infections and subsequent hospitalizations. Breakthrough infection hospitalizations in populations with comorbidities ranged from 26.43% for CKD to 10.23% for chronic lung disease, with corresponding ORs of 2.22 (95% CI: 1.88 - 2.63) and 1.37 (95% CI: 1.21 - 1.55), respectively.
Conclusions Fully-vaccinated individuals with certain comorbidities experienced increased risk of breakthrough COVID-19 infection and subsequent hospitalizations compared to the general population. Individuals with comorbidities should remain vigilant against infection even if vaccinated.
Highlights
COVID-19 infection has greater severity in those with comorbidities.
Here we investigate the risk of breakthrough infections and hospitalizations in fully-vaccinated individuals with and without comorbidities.
We find increased rates of breakthrough infections with all comorbidities, with CKD having the greatest risk.
Individuals with chronic lung disease had the highest rate of breakthrough infection, but the lowest subsequent risk of hospitalization.
Individuals with comorbidities should remain vigilant against infection even if vaccinated.
Competing Interest Statement
All authors are employees of Truveta, Inc.
Funding Statement
This study was funded by Truveta, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was reviewed by the Providence St. Joseph Health Institutional Review Board (IRB) as STUDY2022000212 and determined Not Human Research. 45 CFR 46.102(e)(1).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: All authors are employees of Truveta, Inc.
Ethical Approval: This study was reviewed by the Providence St. Joseph Health Institutional Review Board (IRB) as STUDY2022000212 and determined Not Human Research. 45 CFR 46.102(e)(1).
Data Availability
All data produced in the present study are available with subscription to the Truveta Platform.
https://github.com/Truveta/smits_et_al_covid_breakthrough_comorbidities
